184.25↑4.35 (2.42%)
03:52 PM,6th Dec 2023183.80↑3.90 (2.17%)
04:01 PM,6th Dec 2023BSE : 530199
NSE : THEMISMED
Sector : Health care
ISIN Code : INE083B01024
Last Updated: Dec 06 2023 | 04:01 PM IST
Market Cap (₹ Cr) | 1695 |
Turnover (₹ Cr) | 0.28 |
Volume (Shares) | 151983 |
Face Value | 1 |
52-WK High | 197.17 |
52-WK High Date | 03 Oct 2023 |
52-WK Low | 104.95 |
52-WK Low Date | 06 Dec 2022 |
All Time High | 197.17 |
All Time High Date | 03 Oct 2023 |
All Time Low | 4.00 |
All Time Low Date | 04 Sep 2013 |
Incorporated in 1969 Themis Medicare Ltd. formerly known as Themis Chemicals (TCL) was originally promoted by Chemosyn and Medimpex but was taken over by a group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics which was merged with Artemis Pharmaceuticals in April 93.In Mar.'95 the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi the setting up of a formulation unit at Lilora Baroda as backward integration and to augment long-term working capital.Total cost of the project was estimated at Rs 17.64 cr. TCL manufactures and sells synthetic bulk drugs and formulations. It operates in the therapeutic segments of anti-tuberculosis cerebroactivators bronchodilators anti-asthmatic anaesthetic and other segments.Anti-tuberculosis bulk drugs and formulations account for 60% of its turnover and the company is rated fourth in terms of turnover in this segment. TCL has also started manufacturing and exporting fumagillin an anti-bacterial drug for veterinary use for which it has a confirmed buy-back arrangement with Chinoin Hungary.The company with the help of M/s PharmogradMoscow a manufacturing unit is planning to market its Anti-T.B.formulation products through the collborators throughout the Russian Federation for tradetenders and govt.supplies.
PARAMETER | VALUES |
---|---|
Market Cap (₹ Cr) | 1695 |
EPS - TTM (₹) [S] | 4.11 |
P/E Ratio (X) [S] | 6.45 |
Face Value (₹) | 1 |
Latest Dividend (%) | 50.00 |
Latest Dividend Date | 01 Sep 2023 |
Dividend Yield (%) | 0.27 |
Book Value Share (₹) [S] | 28.57 |
P/B Ratio (₹) [S] | 6.45 |
[*C] Consolidated [*S] Standalone |
Scheme Name ↑↓ | Amount Invested ( ₹ Cr ) ↑↓ | No Of Shares ↑↓ | Net Asset (%) ↑↓ |
---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF | 0.00 | 319 | 0.06 |
Date↑↓ | Broker↑↓ | Action↑↓ | Prices(Rs)↑↓ | Report |
---|---|---|---|---|
Data Not Found |
Today's Low/High | 178.80 187.70 |
Week Low/High | 159.30 187.70 |
Month Low/High | 142.00 187.70 |
Year Low/High | 104.95 197.00 |
All time Low/High | 1.20 197.00 |
Period | BSE | NSE | SENSEX | NIFTY |
---|---|---|---|---|
1 Week | 9.02% | 9.38% | 4.11 | 4.19% |
1 Month | 28.26% | 28.17% | 7.23 | 7.86% |
3 Month | 15.39% | 15.07% | 5.73 | 6.76% |
6 Month | 25.40% | 25.20% | 10.93 | 12.57% |
1 Year | 72.05% | 71.12% | 11.22 | 12.31% |
3 Year | 371.83% | 371.71% | 54.51 | 57.92% |
Non-Exec & Non-Independent Dir : Rajneesh Anand
Independent Non Exe. Director : VIJAY GOPI KISHAN AGARWAL
Independent Non Exe. Director : Hari Subramaniam
Non Executive Director : Reena S Patel
ED / MD / CEO / Promoter : Sachin D Patel
Chairman & Independent Directo : Dinesh S Patel
Independent Non Exe. Director : Manjul Sandhu
Independent Non Exe. Director : Bhaskar Vemban Iyer
Additional Director : Shishir Dalal
Alternate Director : Reena S Patel
Registered Office: Plot No 69 A GIDC Indl Estate, Vapi,Valsad,Gujarat-396195 Ph: 91-260-2421675